Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 5, 2013, Pages 837-843

  Gallicchio, Lisa ^a,b,c   MacDonald, Ryan ^a   Helzlsouer, Kathy J ^a,b  

^a MERCY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Hormonal therapy; Insulin like growth factor 1; Musculoskeletal pain

Indexed keywords

AROMATASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MUSCULOSKELETAL PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MUSCULOSKELETAL PAIN;

EID: 84876286107     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1391-7     Document Type: Article

References (33)

1. Bajetta E, Ferrari L, Celio L, Mariani L, Miceli R, Di Leo A et al (1997) The aromatase inhibitor letrozole in advanced breast cancer: effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 63:261-267
2. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR (1996) Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81:2848-2853
3. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE et al (2002) Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288:2282-2292
4. Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE (2010) A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 120:427-435
5. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
6. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al (2004) A randomized trial of exemestane after 2-3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
7. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup exemestane study): a randomised controlled trial. Lancet 369:559-570
8. Corpas E, Harman SM, Blackman MR (1993) Human growth hormone and human aging. Endocr Rev 14:20-39
9. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790
10. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
11. Ferrari L, Martinetti A, Zilembo N, Pozzi P, Buzzoni R, La Torre I et al (2002) Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol 80:411-418
12. Frost VJ, Helle SI, Lonning PE, van der Stappen JW, Holly JM (1996) Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 81:2216-2221
13. Goss PE (2007) Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat 105:45-53
14. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381-2391
15. Hadji P, Kieback DG, Tams J, Hasenburg A, Ziller M (2012) Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 23:2566-2572
16. Helle SI, Omsjo IH, Hughes SC, Botta L, Huls G, Holly JM, Lonning PE (1996) Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 45:727-732
17. Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E (2012) A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat 131:277-285
18. Henry NL, Giles JT, Stearns V (2008) Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 22:1401-1408
19. Holmes MD, Pollak MN, Hankinson SE (2002) Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:862-867
20. Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, Finckenstein FG, Brodie A, Gottardis MM, Carboni JM, Haluska P (2011) Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 71:7597-7607
21. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
22. Janssen YJ, Helmerhorst F, Frolich M, Roelfsema F (2000) A switch from oral (2 mg/day) to transdermal (50 μg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab 85:464-467
23. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
24. Laroche M, Borg S, Lassoued S, De Lafontan B, Roche H (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 34:2259-2263
25. Lien EA, Johannessen DC, Aakvaag A, Lonning PE (1992) Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 41:541-543
26. Lintermans A, Neven P (2011) Pharmacology of arthralgia with estrogen deprivation. Steroids 76:781-785
27. Lintermans A, Van CB, Van HM, Pans S, Verhaeghe J, Westhovens R et al (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22:1763-1769
28. Litton JK, Arun BK, Brown PH, Hortobagyi GN (2012) Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13:325-331
29. Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7:775-778
30. Raudaskoski T, Knip M, Laatikainen T (1998) Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. Menopause 5:217-222
31. Shanmugam VK, McCloskey J, Elston B, Allison SJ, Eng-Wong J (2012) The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Breast Cancer Res Treat 131:699-708
32. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
33. Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 13:471-483